Standard BioTools Inc. Convertible Preferred Stock, Shares Issued upon Conversion
Standard BioTools Inc. (LAB) had Convertible Preferred Stock, Shares Issued upon Conversion of 46.47 million shares as of 2024-03-18, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Class of Stock Disclosures
us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion · last filed 2026-03-16
- 2024-03-18: Convertible Preferred Stock, Shares Issued upon Conversion 46.47M shares.
| Period end | Convertible Preferred Stock, Shares Issued upon Conversion |
|---|---|
| 2024-03-18 | 46.47M shares 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |